Verified
The morning routine became easier after we linked the tablet with breakfast. The first month brought more appetite, so the dietitian helped us plan filling meals without turning every snack into a restriction.
02 Nov 2026
Active ingredient: Deflazacort
Deflazacort
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Deflazacort is a prescription oral corticosteroid for people with Duchenne muscular dystrophy and selected inflammatory or autoimmune conditions. It helps reduce excessive immune activity after conversion to its active metabolite, deflazacort-21-hydroxide.
Description
Deflazacort is an oral glucocorticoid used for Duchenne muscular dystrophy and selected inflammatory or autoimmune conditions. After conversion to deflazacort-21-hydroxide, it activates glucocorticoid receptors and changes inflammatory signalling.
Composition
Deflazacort contains the active corticosteroid deflazacort and belongs to the glucocorticoid class. Glucocorticoids are synthetic medicines related to hormones produced naturally by the adrenal glands. They influence inflammation, immune activity, carbohydrate metabolism, bone turnover and the body’s response to physical stress.
Deflazacort is chemically related to prednisolone. The tablet is taken by mouth and undergoes conversion in the body before producing its main glucocorticoid activity. The prescribed strength and schedule depend on the condition being treated and the clinical plan.
The active ingredient is deflazacort.
Unlike a local cream or injection, an oral glucocorticoid has systemic effects. This means that it can act throughout the body, which explains both its therapeutic value and the need for monitoring during prolonged treatment.
Dosage and usage
Take Deflazacort exactly according to the prescriber’s schedule. The dose may be adjusted according to the diagnosis, body weight, treatment response, adverse effects and other medicines.
Practical administration points include:
- Take the tablets by mouth at the scheduled time.
- Use the same dosing routine each day.
- Take the medicine with food if it causes stomach discomfort.
- If a dose is missed, follow the prescriber’s missed-dose instructions rather than doubling the next dose.
- Do not stop prolonged treatment suddenly.
- Keep a record of doses for children receiving treatment for DMD.
- Report repeated falls, new muscle pain, back pain or difficulty climbing stairs.
- Attend planned checks for growth, weight, blood pressure, glucose, bone health and eye symptoms.
Long-term corticosteroid therapy can suppress the body’s natural adrenal response. Gradual dose reduction may therefore be needed when treatment ends or changes. The tapering schedule is individual and should not be improvised.
Children taking Deflazacort may need regular height and weight measurements. Adults may need closer assessment of blood pressure, glucose, bone density and cardiovascular risk. Eye examinations become relevant when treatment is prolonged or visual symptoms appear.
Carry a written steroid-treatment record when attending urgent care or hospital. It should include the medicine name, usual schedule, recent dose changes and the condition being treated.
How it works
Deflazacort is converted to the active metabolite deflazacort-21-hydroxide. This metabolite binds to glucocorticoid receptors inside cells and influences gene transcription. The result is reduced production of several inflammatory mediators and lower activity of immune cells involved in excessive inflammation. The effect develops through altered gene activity rather than immediate destruction of inflammatory cells.
In plain language, Deflazacort turns down inflammatory signalling. That can reduce swelling, pain, tissue damage and immune-driven injury. In DMD, its role is different from treating an acute swollen joint: the aim is to support muscle function over time as part of a broader neuromuscular care plan.
The anti-inflammatory and immunosuppressive actions are not limited to one organ. They can also reduce fever or other visible signs of infection, alter glucose control and affect bone remodelling. Corticosteroid treatment therefore requires attention to symptoms that might otherwise seem minor.
The United States Food and Drug Administration describes deflazacort as a glucocorticoid for DMD, while specialist guidance places corticosteroid treatment within multidisciplinary neuromuscular care [1].
A fever, persistent cough, unusual tiredness or worsening pain deserves prompt attention during steroid treatment because inflammatory signs can be less obvious when immune activity is suppressed.
Indications
Deflazacort is a prescription corticosteroid with an established role in Duchenne muscular dystrophy (DMD), a genetic condition that causes progressive muscle weakness. In DMD, corticosteroid treatment can help preserve muscle function and prolong mobility when used within a specialist treatment plan. The choice of corticosteroid depends on the patient’s age, body weight, muscle status, treatment goals and previous exposure to steroids.
Deflazacort may also be prescribed for selected inflammatory or autoimmune disorders. These can include rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, juvenile idiopathic arthritis and polymyalgia rheumatica. Use outside an approved indication should be directed by a clinician familiar with corticosteroid treatment.
DMD treatment is long term.
Corticosteroids affect many body systems. The same immune-suppressing activity that reduces inflammation can also influence bones, glucose regulation, growth, mood, blood pressure and infection responses. Specialist follow-up is therefore part of treatment, especially for children and adolescents.
For a child taking Deflazacort for DMD, keep a simple daily record of the dose, missed doses, infections, falls, pain and major changes in appetite or mood. This gives the clinical team useful information at review appointments.
Comparison
Deflazacort is one systemic corticosteroid option. It is not automatically the best choice for every inflammatory disease or every person with DMD. Prednisone, prednisolone, methylprednisolone and dexamethasone have different clinical roles, potency profiles, dosing schedules and formulation options.
| Corticosteroid | Common clinical role | Main monitoring considerations |
|---|---|---|
| Deflazacort | DMD and selected inflammatory or autoimmune conditions | Growth, weight, bones, glucose, blood pressure, infection and eyes |
| Prednisone or prednisolone | Broad inflammatory, autoimmune and neuromuscular use | Weight, appetite, mood, glucose, blood pressure and bone health |
| Methylprednisolone or dexamethasone | Acute inflammation, specialist protocols or severe disease | Glucose, infection, mood, blood pressure, muscle and bone effects |
Methylprednisolone is also used in several formulations, including oral and injectable forms. Depo-Medrol, Medrol, Solu-Medrol and methylprednisolone dose packs refer to methylprednisolone formulations or branded presentation names, not to Deflazacort.
A direct dose conversion should not be guessed. Glucocorticoid potency varies between medicines, and the appropriate conversion depends on the clinical context, route, duration and treatment objective. The European Medicines Agency has described glucocorticoid-related considerations in regulatory guidance for Duchenne muscular dystrophy treatments [2].
Some studies report different patterns of weight gain or growth effects between deflazacort and prednisone, yet these findings do not remove the need for monitoring. A lower tendency in one adverse-effect area does not mean that bone, eye, metabolic or infection risks disappear.
Contraindications
Tell the prescriber about:
- An active infection or recent close exposure to a serious infection
- Diabetes or previous high blood glucose
- High blood pressure or heart disease
- Osteoporosis, fractures or persistent bone pain
- Cataracts, glaucoma or other eye disease
- A stomach ulcer or previous gastrointestinal bleeding
- Epilepsy or other neurological conditions
- Depression, psychosis, severe anxiety or major mood changes
- Recent surgery or planned surgery
- Liver or kidney disease
- Pregnancy, planned pregnancy or breastfeeding
- Previous allergic reactions to corticosteroids
Deflazacort’s immunosuppressive activity can change vaccine planning. Live vaccines may require special consideration during significant immunosuppression, while other vaccines may produce a weaker immune response. Vaccine decisions should be made with the treating clinician rather than handled through self-treatment.
Drug interactions are also relevant. Medicines that alter liver enzymes can change corticosteroid exposure, and combinations with other immunosuppressive treatments may increase infection risk. Diabetes medicines, anticoagulants, certain anticonvulsants and medicines affecting blood pressure may require closer monitoring after Deflazacort is started or adjusted.
When this is not for you
This medication is not for you if a prescriber has identified a serious contraindication, a dangerous interaction or an untreated infection that makes systemic corticosteroid treatment unsuitable. Emergency help is needed for severe breathing difficulty, facial swelling, sudden confusion, severe weakness or signs of a serious infection.
Side effects
Deflazacort can cause adverse effects because glucocorticoid receptors are present in many tissues. Risk tends to increase with higher exposure and longer treatment, although individual responses vary.
Possible effects include:
- Increased appetite and weight gain
- Difficulty sleeping or changes in mood
- Indigestion or stomach discomfort
- Increased blood pressure
- Raised blood glucose
- Greater susceptibility to infection
- Acne or skin changes
- Muscle weakness after prolonged exposure
- Bone loss or corticosteroid-induced osteoporosis
- Cataracts or raised pressure inside the eye
- Slowed growth in children
A child’s height may increase more slowly during prolonged corticosteroid treatment. Weight gain can also alter mobility and place additional strain on weakened muscles in DMD. These effects need practical management rather than silent acceptance; the clinical team may review nutrition, physical activity, treatment timing and the corticosteroid plan.
Bone health deserves special attention. Repeated falls, persistent back pain, limb pain or a sudden reduction in walking ability can indicate a fracture or vertebral problem and require prompt assessment. Calcium or vitamin D supplements should not be started automatically because the correct approach depends on diet, blood tests, kidney function, age and fracture risk.
New blurred vision, halos around lights or eye pain requires medical assessment. Fever, breathing difficulty or unusual weakness can also be significant during immunosuppressive treatment.
Do not assume that a lower weight-gain risk compared with prednisone means weight and bone checks can be skipped. Deflazacort still has glucocorticoid effects throughout the body.
Common mistakes
Common mistakes include:
- Stopping the medicine suddenly after months of treatment
- Doubling a dose after a missed tablet
- Treating repeated falls as an unavoidable part of DMD
- Ignoring back pain or new difficulty walking
- Missing appointments because the person appears stable
- Assuming a reduced appetite or stable weight means there is no steroid effect
- Starting calcium, vitamin D or herbal products without checking for interactions
- Receiving a live vaccine without discussing current immunosuppression
- Failing to mention Deflazacort before surgery or emergency treatment
One practical detail is easy to miss: a child’s school or care team should know that the child takes long-term corticosteroids and should know whom to contact if fever, vomiting, injury or sudden weakness occurs.
Another is the relationship between falls and bone health. A new pattern of falls, refusal to climb stairs or reluctance to walk can signal pain, fatigue or a fracture rather than simple behavioural change.
What doctors say
In clinical practice, the main decision is not simply whether Deflazacort reduces inflammation. The prescriber also weighs function, growth, weight, bone health, glucose regulation, infection risk and the expected duration of therapy.
For DMD, corticosteroid benefit is assessed over time. A treatment plan may include physiotherapy, respiratory follow-up, cardiac assessment, nutritional support, orthopaedic review and regular functional measurements. Deflazacort is one part of that plan.
The World Health Organization identifies glucocorticoids as medicines that require careful risk-benefit assessment because systemic effects can involve immunity, metabolism and bone health [3].
Frequently asked questions
Is Deflazacort used for Duchenne muscular dystrophy?
Yes. Deflazacort is used as a corticosteroid treatment option for DMD, where it may help preserve muscle function and mobility as part of specialist care. The FDA-approved indication for deflazacort includes DMD, and clinical decisions still depend on age, weight, disease stage and the wider neuromuscular plan (FDA, 2017). The treatment schedule must come from the prescriber.
How does Deflazacort differ from prednisone or prednisolone?
Deflazacort, prednisone and prednisolone are systemic glucocorticoids, but they differ in chemical structure, potency, dosing and adverse-effect patterns. Some comparative research has found differences in weight gain, growth or bone-related outcomes, yet no option removes the need for follow-up. Specialist DMD guidance published by NICE supports corticosteroid use within coordinated multidisciplinary management (NICE, 2016) [4].
Can Deflazacort cause weight gain?
Yes. Increased appetite and weight gain can occur with Deflazacort, especially during prolonged treatment. Weight changes may be more significant in children with DMD because additional body mass can make movement and transfers harder. Monitoring should include weight, growth, nutrition, activity and treatment response rather than relying on appetite alone. The FDA prescribing information from 2017 lists weight gain among possible corticosteroid effects.
Why must Deflazacort not be stopped suddenly?
Long-term glucocorticoid treatment can reduce the body’s own adrenal cortisol production. Sudden withdrawal may lead to steroid withdrawal symptoms or adrenal insufficiency, including marked weakness, nausea, low blood pressure and collapse. The FDA prescribing information recommends gradual reduction when clinically appropriate rather than abrupt cessation (FDA, 2017).
How are bone and eye risks monitored?
Monitoring may include review of falls, bone pain, mobility changes, height, weight, vitamin status, fracture risk and, when indicated, bone-density assessment. Eye review is important when visual symptoms occur or treatment continues for a prolonged period, with attention to cataracts and raised intraocular pressure. The Cochrane evidence review on glucocorticoids for DMD supports ongoing assessment of benefits and adverse effects during long-term corticosteroid treatment (Cochrane, 2016) [5].
Can Deflazacort affect vaccines and infections?
Yes. Immunosuppressive treatment can alter vaccine planning and may make some infection symptoms less obvious. Live vaccines may be unsuitable during substantial immunosuppression, while vaccine responses can vary with treatment intensity. The WHO advises that immunisation decisions account for the person’s immune status, medicine exposure and infection risk (WHO, 2020).
Is Deflazacort suitable for every inflammatory disease?
No. Deflazacort may be used in selected inflammatory or autoimmune disorders, yet the appropriate corticosteroid depends on the diagnosis, disease severity, treatment duration and previous therapy. Rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, juvenile idiopathic arthritis and polymyalgia rheumatica require different treatment strategies. A prescriber determines whether systemic corticosteroid treatment is appropriate. NICE guidance from 2016 describes corticosteroid decisions as diagnosis-specific and specialist-led.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Deflazacort: Reviews and Experiences
3.6
Based on 4 reviews
Verified
My joint stiffness improved, and I could manage ordinary morning tasks again. Sleep was worse during the first weeks, so the prescriber reviewed the timing rather than increasing the dose.
06 Nov 2026
Verified
The medicine seemed helpful for mobility, but weight gain became a concern. We kept missing the weight checks, and the clinic reminded us that stable walking does not remove the need for monitoring.
10 Oct 2026
Verified
I felt better and stopped the tablets without a taper. Within days I became very weak and unwell. The experience made it clear that stopping a long-term steroid needs a planned reduction.
22 Oct 2026
Sources
- U.S. Food and Drug Administration (2017). EMFLAZA (deflazacort) prescribing information.
- European Medicines Agency (2015). Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy.
- World Health Organization (2020). Immunization in the context of COVID-19 pandemic: frequently asked questions.
- National Institute for Health and Care Excellence (2016). Duchenne muscular dystrophy: diagnosis and management (NG43).
- Cochrane (2016). Glucocorticoids for Duchenne muscular dystrophy.
